Last reviewed · How we verify
NCT05481190
The Impact Of A Tele-Exercise Program For Children With Cystic Fibrosis During The Covid-19 Pandemic On Quality Of Life
NA trial testing Tele-Exercise Program in Cystic Fibrosis in 34 participants. Completed in 15 February 2022.
15 September 2021
Quick facts
| Lead sponsor | Ondokuz Mayıs University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 34 |
| Start date | 1 April 2021 |
| Primary completion | 15 September 2021 |
| Estimated completion | 15 February 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Tele-Exercise Program
- Just observation
Conditions studied
- Cystic Fibrosis — all drugs for Cystic Fibrosis →
- Exercise Addiction — all drugs for Exercise Addiction →
- Nursing Caries — all drugs for Nursing Caries →
- Quality of Life — all drugs for Quality of Life →
Sponsor
Ondokuz Mayıs University
Who can join
Adults 10 to 18, any sex, with Cystic Fibrosis or Exercise Addiction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study was to examine the effect of the tele-exercise program applied to children with cystic fibrosis in the Covid-19 pandemic on the quality of life and the symptoms experienced during exercise
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05481190
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cystic Fibrosis
Currently open trials in the same condition.
- NCT07437105 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants · Phase 1 · recruiting
- NCT07283770 — Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants · Phase 1 · recruiting
- NCT07274631 — A Cohort for Inflammatory Respiratory Diseases: From Phenotyping to Personalised Medicine · recruiting
- NCT06810167 — Assessing Tenapanor as a Treatment of CF-related Constipation. · Phase 3 · recruiting
- NCT06962852 — A Long-term Study to Monitor the Health Status of People With Cystic Fibrosis Who Took Part in a Previous Study With BI · Phase 1, PHASE2 · active not recruiting
Other Ondokuz Mayıs University trials
Trials by the same sponsor.
- NCT07500389 — Postural Habits, Body Awareness, and Functional Performance Across BMI Categories in Women · not yet recruiting
- NCT07535242 — Serum GFAP, NfL, VEGF and Clinical Progression in Progressive MS · not yet recruiting
- NCT07504848 — Stroke Mobility and Caregiver Outcomes · not yet recruiting
- NCT07525557 — Kinesiophobia, Pain and Disability in Chronic Neck Pain · recruiting
- NCT07497802 — Mindfulness-Based Psychoeducation for Women With Gynecological Cancer · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05481190 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ondokuz Mayıs University
- Last refreshed: 20 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05481190.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing